Type 2 Diabetes

Li and Shao discussed the T2D risk reduction seen over the course of the VA MOVE! lifestyle intervention program for veterans.

Isaacs and Bellini walk through the newly released Preexisting Diabetes in Pregnancy guidelines, discussing each of the 10 recommendations.

Findings showed GLP-1 RAs reduced the risk of overall dementia, particularly Alzheimer’s disease and non-vascular dementias, compared with metformin.

Steger discussed the importance of tailoring diet strategies to patients with type 2 diabetes.

Shah discusses the stagnation of the T1D treatment landscape and the potential progress that GLP-1 RA research could present.

Philis-Tsimikas emphasized the impact of nonmedical factors on health and how clinicians can be cognizant of them in their patient management.

Isaacs and Bellini discuss 3 more of the most impactful trials presented at the 85th annual American Diabetes Association conference in part 2 of this 2-part recap.

Isaacs and Bellini cover 3 of the most pivotal trial results from the 85th annual American Diabetes Association conference in part 1 of this 2-part recap.

Auchus discusses his recent presentation on the CATALYST trial, investigating the characteristics of patients with difficult-to-treat T2D because of hypercortisolism.

Lifestyle intervention yielded greater maintained weight loss 12 months after discontinuing semaglutide than without.

An audio recap of the top 5 stories in healthcare news from the week of 06/30-07/06.

Sandforth discussed his research that found that early prediabetes remission conferred greater protective effects against T2D than later remission.

Hosts discuss the US launch of the Twiist from Sequel Med Tech and what it means for care providers and people with diabetes.

Explore key advancements in endocrinology from Q2 2025, including FDA approvals and groundbreaking diabetes research shaping future treatments.

June 2025 highlights groundbreaking advancements in endocrinology, featuring key insights from major conferences on diabetes, heart health, and kidney care.

From uncovering new benefits of semaglutide to targeting hypercortisolism in people with type 2 diabetes, here are 5 key updates from the annual meeting.

Verma discussed how recent advances in the field affect clinician management of type 2 diabetes and peripheral artery disease.

Verma discussed how new data from the STRIDE trial support the role of GLP-1 RAs as protective vascular medications.

This recap highlights data on stem cell-derived therapies for type 1 diabetes, cortisol-modulating strategies for hard-to-treat type 2 diabetes, and a novel once-weekly insulin alternative that matches daily injections in efficacy.

Read the latest pivotal data on once-monthly injectables, oral GLP-1 agonists, and novel co-agonist therapies from ADA.

A recent cross-sectional analysis has estimated the size of the American population with both MASLD and T2DM eligible for treatment.

Verma went over the STRIDE trial evaluating the GLP-1 RA and its latest findings presented at ADA Scientific Sessions.

Mifepristone shows promise in improving glycemic control and reducing weight in patients with hypercortisolism and type 2 diabetes.

Maridebart cafraglutide shows potential as a monthly treatment for obesity and type 2 diabetes, demonstrating significant weight loss and glycemic improvements.

A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes.